InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.99
(
-0.15%
)
US TECH 100
19,191.20
(
-0.35%
)
Dow Jones
39,241.16
(
0.27%
)
Brent Oil
85.13
(
0.14%
)
Bitcoin
64,067.00
(
-1.16%
)
Post# of 252283
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119885
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pollyvonwog post# 173442

Thursday, 01/30/2014 2:53:44 PM

Thursday, January 30, 2014 2:53:44 PM

Post# of 252283

What would stop MNTA or MYL from submitting an ANDA for thrice-weekly [Copaxone] as well (assuming approval of their generic copax of course)?

It would be technically easy; however, it might not be worth the effort, especially if both companies get approval for generic versions of regular Copaxone.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up